Abstract 204P
Background
Precision oncology is a rapidly evolving field. Reliable tools are required for comprehensive genomic profiling (CGP) in clinical and research settings. NGS provides capabilities to detect multiple alterations, but complex workflows may be difficult to implement. Roche Diagnostics and Foundation Medicine have developed the AVENIO Tumor Tissue CGP Kit, a streamlined and easy to implement Research-Use-Only CGP assay to enable translational research labs.
Methods
The AVENIO Tumor Tissue CGP Kit profiles 324 genes for cancer alterations, tumor mutation burden (TMB), microsatellite instability (MSI), and genomic loss of heterozygosity (gLOH)). The kit contains reagents to create libraries. A software provides access to Foundation Medicine’s bioinformatics pipeline. Five laboratories tested 160 samples, consisting of cell line and formalin fixed paraffin embedded (FFPE) tumor specimens. To assess reproducibility, 144 samples were evaluated across operators, lots, and instruments. To evaluate diagnostic sensitivity and specificity, 314 FFPE samples were tested and positive and negative predictive agreements determined against an orthogonal NGS method.
Results
Across five labs, pass rate was 98.1%. Sequencing quality metrics were high, with most samples reaching 1500x-2500x median coverage. Sites had 99.7% agreement for short variants. In the 144 sample reproducibility study, samples were highly uniform across variables, achieving >90% on-target rate. In the 314 sample concordance study, pass rate was 99.06%, with most samples achieving 2000x-2500x median coverage. Out of 314 samples, PPA to an orthogonal NGS-based method were: 98.3% short variants, 90.5% rearrangements, 94.8% copy number, 100% MSI, 100% TMB, and 96.8% gLOH. NPA reached 99.97% across short variants. Detected alterations included EGFR T7090M, BRAF V600E, KRAS 12/13 mutations, and EML4-ALK fusions.
Conclusions
CGP tests are being utilized in precision oncology, but NGS workflows and bioinformatics pipelines can be difficult to implement. The AVENIO CGP Tumor Tissue Kit is highly reproducible across sites and operators, achieving high sequencing quality metrics and diagnostic sensitivity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Roche Diagnostics Solutions.
Funding
Roche Diagnostics Solutions.
Disclosure
J. Choi, A. Ahmed, K. Bi, K. Kirkconnell, C. Yin, M. Shin, N. Shrestha, J. Blau, S. Li, Y. Li, G. Kumar, R. Chien, W. Wen, Z. Li: Other, Institutional, Full or part-time Employment: Roche Diagnostics. A. Fellowes, E. Pikarsky : Other, Institutional, Sponsor/Funding, Roche sponsored study: Roche Diagnostics. M. Teixeira: Other, Institutional, Sponsor/Funding, Roche Sponsored Study: Roche Diagnostics; Other,Speaker, Consultant, Advisor: AstraZeneca Produtos Farmacêuticos; Other, Speaker, Consultant, Advisor: Janssen Cilag Farmacêutica, Merck Sharp & Dohme, Novartis Farma Produtos Farmacêuticos, Roche Farmacêutica Química , Roche Sistemas De Diagnósticos Sociedade Unipessoal. I. Vogl, S.E. Trabucco: Other, Institutional, Full or part-time Employment: Foundation Medicine. M. Javey: Other, Institutional, Full or part-time Employment, Stocks: Roche Diagnostics.
Resources from the same session
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01
176P - Enhancing immunotherapy response prediction via multimodal integration of radiology and pathology deep learning models
Presenter: Marta Ligero
Session: Poster session 01
177P - Revealing differences in radiosensitivity of advanced non-small cell lung cancer (NSCLC)through single-cell sequencing data
Presenter: Peimeng You
Session: Poster session 01
178P - Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
Presenter: Leonardo Provenzano
Session: Poster session 01
179P - Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study
Presenter: Dhruv Bansal
Session: Poster session 01
180P - An HLA-diet-oriented system unveiling organ-specific occurrence of multiple primary cancers (MPC) with prevention strategy: A large cohort study of 47,550 cancer patients
Presenter: Zixuan Rong
Session: Poster session 01
181P - GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative
Presenter: Philippe Aftimos
Session: Poster session 01
182P - ALK fusion detection by RNA next-generation sequencing (NGS) compared to DNA in a large, real-world non-small cell lung cancer (NSCLC) dataset
Presenter: Wade Iams
Session: Poster session 01
183P - Frequency of actionable fusions in 7,735 patients with solid tumors
Presenter: Kevin McDonnell
Session: Poster session 01
184P - Patient-specific HLA-I genotypes predict response to immune checkpoint blockade
Presenter: Kyrillus Shohdy
Session: Poster session 01